Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15525744 | 0.84 | ABL1 (0.54) | MAPTNPC1RAB9AABL1ABCB1 | |
| SCHEMBL30294336 | 0.83 | MAPT (0.54) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL838442 | 0.83 | MAPT (0.54) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL4303038 | 0.82 | ALDH1A1 (0.55) | MAPTNPC1RAB9ATP53ESR2 | |
| SCHEMBL2097981 | 0.81 | DYRK1A (0.55) | MAPTNPC1RAB9ADYRK1AABL1 | |
| SCHEMBL1257369 | 0.81 | MAPT (0.53) | MAPTNPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL12440897 | 0.79 | ALDH1A1 (0.46) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL876226 | 0.78 | CYP11B1 (0.49) | NPC1RAB9ADYRK1AABL1ABCB1 | |
| SCHEMBL22609962 | 0.78 | KIF11 (0.44) | MAPTMAPK1CA12CA9 | |
| SCHEMBL15342387 | 0.78 | DYRK1A (0.52) | MAPTNPC1RAB9ADYRK1AABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618690-B2 | Polymerizable liquid crystal compound, liquid crystal composition, optical anisotropic material and optical element | ASAHI GLASS COMPANY, LIMITED (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7618690-B2 | Polymerizable liquid crystal compound, liquid crystal composition, optical anisotropic material and optical element | ASAHI GLASS COMPANY, LIMITED (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | ASAHI GLASS COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | ASAHI GLASS COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080204650-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, OPTICAL ANISOTROPIC MATERIAL AND OPTICAL ELEMENT | CCNE2, CCNE1, CCNL2 | MAPT 952/4885NPC1 3578/4885RAB9A 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.